NR3C2 and metastatic prostate carcinoma: Intriguingly, a genetic polymorphism in MR was associated with prognosis in androgen-deprivation therapy for metastatic prostate cancer, suggesting that MR plays a key role in the resistance of prostate cancer to AR axis-targeting therapies [134].